PRESS RELEASE




Statement of total voting rights and shares forming the
company’s share capital as of November 4, 2024

Article R. 22-10-23 of the French Commercial Code

Market : Euronext Paris
ISIN code / Mnemo : FR0013233012 / IVA
Web site : www.inventivapharma.com



Number of Shares Total voting rights, Total voting rights,
Date
Outstanding gross (1) net (2)

November 4, 2024 87 077 695 100 059 052 99 938 530

(1)
The total number of gross (or “theoretical”) voting rights is used as the basis for calculating threshold crossings. In accordance with
Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached,
including those for which voting rights have been suspended.

(2)
The total number of net (or “exercisable at a Shareholders’ Meeting”) voting rights is calculated without taking into account shares
for which voting rights have been suspended, i.e. treasury shares (including shares purchased under the liquidity contract). It is
released in order to ensure that the public is properly informed.




About Inventiva

Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small
molecule therapies for the treatment of patients with MASH/NASH and other diseases with significant unmet
medical need. The Company benefits from a strong expertise and experience in the domain of compounds
targeting nuclear receptors, transcription factors and epigenetic modulation. Inventiva is currently advancing one
clinical candidate, has a pipeline of two preclinical programs and continues to explore other development
opportunities to add to its pipeline.

Inventiva’s lead product candidate, lanifibranor, is currently in a pivotal Phase 3 clinical trial, NATiV3, for the
treatment of adult patients with MASH/NASH, a common and progressive chronic liver disease.

Inventiva’s pipeline also includes odiparcil, a drug candidate for the treatment of adult MPS VI patients. As part
of Inventiva’s decision to focus clinical efforts on the development of lanifibranor, it suspended its clinical efforts
relating to odiparcil and is reviewing available options with respect to its potential further development. Inventiva
is also in the process of selecting a candidate for its Hippo signaling pathway program.

The Company has a scientific team of approximately 90 people with deep expertise in the fields of biology,
medicinal and computational chemistry, pharmacokinetics and pharmacology, and clinical development. It owns
an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which
are proprietary, as well as a wholly-owned research and development facility.

Inventiva is a public company listed on compartment B of the regulated market of Euronext Paris (ticker: IVA, ISIN:
FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). www.inventivapharma.com


1
PRESS RELEASE




Contacts

Inventiva Brunswick Group ICR Healthcare
Pascaline Clerc Tristan Roquet Montegon / Patricia L. Bank
EVP, Strategy and Corporate Affairs Aude Lepreux / Investor relations
media@inventivapharma.com Julia Cailleteau patti.bank@westwicke.com
+1 202 499 8937 Media relations +1 415 513-1284
inventiva@brunswickgroup.com
+33 1 53 96 83 83

Important Notice

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included
in this press release are forward-looking statements.

These statements include, but are not limited to, forecasts and estimates with respect to Inventiva’s pre-clinical
programs and clinical trials, including design, duration, timing, recruitment costs, screening and enrollment for
those trials, including the ongoing NATiV3 Phase III clinical trial with lanifibranor in MASH/NASH, clinical trial data
releases and publications, the information, insights and impacts that may be gathered from clinical trials, the
potential therapeutic benefits of Inventiva’s product candidates, including lanifibranor, potential regulatory
submissions, approvals and commercialization, Inventiva’s pipeline and preclinical and clinical development plans,
the expected benefit of having received Breakthrough Therapy Designation, including its impact on the
development and review timeline of Inventiva’s product candidates, the potential development of and regulatory
pathway for odiparcil, and future activities, expectations, plans, growth and prospects of Inventiva and its
partners. Certain of these statements, forecasts and estimates can be recognized by the use of words such as,
without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will”,
“would”, “could”, “might”, “should”, “designed”, “hopefully”, “target”, “potential”, “opportunity”, “possible”,
“aim”, and “continue” and similar expressions. Such statements are not historical facts but rather are statements
of future expectations and other forward-looking statements that are based on management's beliefs. These
statements reflect such views and assumptions prevailing as of the date of the statements and involve known and
unknown risks and uncertainties that could cause future results, performance, or future events to differ materially
from those expressed or implied in such statements. Actual events are difficult to predict and may depend upon
factors that are beyond Inventiva's control. There can be no guarantees with respect to pipeline product candidates
that the clinical trial results will be available on their anticipated timeline, that future clinical trials will be initiated
as anticipated, that product candidates will receive the necessary regulatory approvals, or that any of the
anticipated milestones by Inventiva or its partners will be reached on their expected timeline, or at all. Future
results may turn out to be materially different from the anticipated future results, performance or achievements
expressed or implied by such statements, forecasts and estimates, due to a number of factors, including that
Inventiva cannot provide assurance on the impacts of the Suspected Unexpected Serious Adverse Reaction (SUSAR)
on enrollment or the ultimate impact on the results or timing of the NATiV3 trial or regulatory matters with respect
thereto, that Inventiva is a clinical-stage company with no approved products and no historical product revenues,
Inventiva has incurred significant losses since inception, Inventiva has a limited operating history and has never
generated any revenue from product sales, Inventiva will require additional capital to finance its operations, in the
absence of which, Inventiva may be required to significantly curtail, delay or discontinue one or more of its research
or development programs or be unable to expand its operations or otherwise capitalize on its business
opportunities and may be unable to continue as a going concern, Inventiva’s ability to obtain financing and to
enter into potential transactions, Inventiva's future success is dependent on the successful clinical development,
regulatory approval and subsequent commercialization of current and any future product candidates, preclinical
studies or earlier clinical trials are not necessarily predictive of future results and the results of Inventiva's and its
partners’ clinical trials may not support Inventiva's and its partners’ product candidate claims, Inventiva's
expectations with respect to its clinical trials may prove to be wrong and regulatory authorities may require holds
2
PRESS RELEASE



and/or amendments to Inventiva’s clinical trials, Inventiva’s expectations with respect to the clinical development
plan for lanifibranor for the treatment of MASH/NASH may not be realized and may not support the approval of a
New Drug Application, Inventiva and its partners may encounter substantial delays beyond expectations in their
clinical trials or fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities, the
ability of Inventiva and its partners to recruit and retain patients in clinical studies, enrollment and retention of
patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered
impossible by multiple factors outside Inventiva's and its partners’ control, Inventiva's product candidates may
cause adverse drug reactions or have other properties that could delay or prevent their regulatory approval, or
limit their commercial potential, Inventiva faces substantial competition and Inventiva’s and its partners' business,
and preclinical studies and clinical development programs and timelines, its financial condition and results of
operations could be materially and adversely affected by geopolitical events, such as the conflict between Russia
and Ukraine and related sanctions, impacts and potential impacts on the initiation, enrollment and completion of
Inventiva’s and its partners’ clinical trials on anticipated timelines and the state of war between Israel and Hamas
and the related risk of a larger conflict, health epidemics, and macroeconomic conditions, including global
inflation, rising interest rates, uncertain financial markets and disruptions in banking systems. Given these risks
and uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements,
forecasts, and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the
date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking
statements.

Please refer to the Universal Registration Document for the year ended December 31, 2023, filed with the Autorité
des Marchés Financiers on April 3, 2024 as amended on October 14, 2024, and the Annual Report on Form 20-F
for the year ended December 31, 2023, filed with the Securities and Exchange Commission on April 3, 2024, and
the Half-Year Report for the six months ended June 30, 2024 on Form 6-K filed with the SEC on October 15, 2024.
Other risks and uncertainties of which Inventiva is not currently aware may also affect its forward-looking
statements and may cause actual results and the timing of events to differ materially from those anticipated. All
information in this press release is as of the date of the release. Except as required by law, Inventiva has no
intention and is under no obligation to update or review the forward-looking statements referred to above.
Consequently, Inventiva accepts no liability for any consequences arising from the use of any of the above
statements.




3